Search

Your search keyword '"Conconi, Annarita"' showing total 46 results
Start Over Author "Conconi, Annarita" Publication Year Range Last 10 years
46 results on '"Conconi, Annarita"'

1. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

Author

Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, and Luminari, Stefano

Published
2024
Full Text
View/download PDF

2. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma

Author

Conconi, Annarita, Chiappella, Annalisa, Ferreri, Andrés J. M., Stathis, Anastasios, Botto, Barbara, Sassone, Marianna, Gaidano, Gianluca, Balzarotti, Monica, Merli, Francesco, Tucci, Alessandra, Vanazzi, Anna, Tani, Monica, Bruna, Riccardo, Orsucci, Lorella, Cabras, Maria Giuseppina, Celli, Melania, Annibali, Ombretta, Liberati, Anna Marina, Zanni, Manuela, Ghiggi, Chiara, Pisani, Francesco, Pinotti, Graziella, Dore, Fausto, Esposito, Fabiana, Pirosa, Maria Cristina, Cesaretti, Marina, Bonomini, Luisella, Vitolo, Umberto, and Zucca, Emanuele

Published
2024
Full Text
View/download PDF

4. Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature

Author

Bommier, Côme, Link, Brian K., Gysbers, Brianna J., Maurer, Matthew J., Larson, Melissa C., Khurana, Arushi, Wang, Yucai, Thompson, Carrie A., Chihara, Dai, Alderuccio, Juan P., Koff, Jean L., Epperla, Narendranath, Conconi, Annarita, Lossos, Izidore S., Nowakowski, Grzegorz S., Feldman, Andrew L., Habermann, Thomas M., King, Rebecca L., and Cerhan, James R.

Published
2024
Full Text
View/download PDF

5. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Author

Visco, Carlo, Marcheselli, Luigi, Mina, Roberto, Sassone, Marianna, Guidetti, Anna, Penna, Domenico, Cattaneo, Chiara, Bonuomo, Valentina, Busca, Alessandro, Ferreri, Andrés José María, Bruna, Riccardo, Petrucci, Luigi, Cairoli, Roberto, Salvini, Marco, Bertù, Lorenza, Ladetto, Marco, Pilerci, Sofia, Pinto, Antonello, Ramadan, Safaa, Marchesi, Francesco, Cavo, Michele, Arcaini, Luca, Coviello, Elisa, Romano, Alessandra, Musto, Pellegrino, Massaia, Massimo, Fracchiolla, Nicola, Marchetti, Monia, Scattolin, Annamaria, Tisi, Maria Chiara, Cuneo, Antonio, Della Porta, Matteo, Trentin, Livio, Turrini, Marco, Gherlinzoni, Filippo, Tafuri, Agostino, Galimberti, Sara, Bocchia, Monica, Cardinali, Valeria, Cilloni, Daniela, Corso, Alessandro, Armiento, Daniele, Rigacci, Luigi, La Barbera, Elettra Ortu, Gambacorti-Passerini, Carlo, Visani, Giuseppe, Vallisa, Daniele, Venditti, Adriano, Selleri, Carmine, Conconi, Annarita, Tosi, Patrizia, Lanza, Francesco, Candoni, Anna, Krampera, Mauro, Corradini, Paolo, Passamonti, Francesco, and Merli, Francesco

Published
2022
Full Text
View/download PDF

6. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Author

Passamonti, Francesco, Cattaneo, Chiara, Arcaini, Luca, Bruna, Riccardo, Cavo, Michele, Merli, Francesco, Angelucci, Emanuele, Krampera, Mauro, Cairoli, Roberto, Della Porta, Matteo Giovanni, Fracchiolla, Nicola, Ladetto, Marco, Gambacorti Passerini, Carlo, Salvini, Marco, Marchetti, Monia, Lemoli, Roberto, Molteni, Alfredo, Busca, Alessandro, Cuneo, Antonio, Romano, Alessandra, Giuliani, Nicola, Galimberti, Sara, Corso, Alessandro, Morotti, Alessandro, Falini, Brunangelo, Billio, Atto, Gherlinzoni, Filippo, Visani, Giuseppe, Tisi, Maria Chiara, Tafuri, Agostino, Tosi, Patrizia, Lanza, Francesco, Massaia, Massimo, Turrini, Mauro, Ferrara, Felicetto, Gurrieri, Carmela, Vallisa, Daniele, Martelli, Maurizio, Derenzini, Enrico, Guarini, Attilio, Conconi, Annarita, Cuccaro, Annarosa, Cudillo, Laura, Russo, Domenico, Ciambelli, Fabrizio, Scattolin, Anna Maria, Luppi, Mario, Selleri, Carmine, Ortu La Barbera, Elettra, Ferrandina, Celestino, Di Renzo, Nicola, Olivieri, Attilio, Bocchia, Monica, Gentile, Massimo, Marchesi, Francesco, Musto, Pellegrino, Federici, Augusto Bramante, Candoni, Anna, Venditti, Adriano, Fava, Carmen, Pinto, Antonio, Galieni, Piero, Rigacci, Luigi, Armiento, Daniele, Pane, Fabrizio, Oberti, Margherita, Zappasodi, Patrizia, Visco, Carlo, Franchi, Matteo, Grossi, Paolo Antonio, Bertù, Lorenza, Corrao, Giovanni, Pagano, Livio, and Corradini, Paolo

Published
2020
Full Text
View/download PDF

7. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

Author

Stathis, Anastasios, primary, Pirosa, Maria Cristina, additional, Orsucci, Lorella, additional, Feugier, Pierre, additional, Tani, Monica, additional, Ghesquières, Hervé, additional, Musuraca, Gerardo, additional, Rossi, Francesca Gaia, additional, Merli, Francesco, additional, Guièze, Romain, additional, Gyan, Emmanuel, additional, Gini, Guido, additional, Marino, Dario, additional, Gressin, Remy, additional, Morschhauser, Franck, additional, Cavallo, Federica, additional, Palombi, Francesca, additional, Conconi, Annarita, additional, Tessoulin, Benoît, additional, Tilly, Hervé, additional, Zanni, Manuela, additional, Cabras, Maria Giuseppina, additional, Capochiani, Enrico, additional, Califano, Catello, additional, Celli, Melania, additional, Pulsoni, Alessandro, additional, Angrilli, Francesco, additional, Occhini, Ubaldo, additional, Casasnovas, René-Olivier, additional, Cartron, Guillaume, additional, Devizzi, Liliana, additional, Haioun, Corinne, additional, Liberati, Anna Marina, additional, Houot, Roch, additional, Merli, Michele, additional, Pietrantuono, Giuseppe, additional, Re, Francesca, additional, Spina, Michele, additional, Landi, Francesco, additional, Cavalli, Franco, additional, Bertoni, Francesco, additional, Rossi, Davide, additional, Ielmini, Nicoletta, additional, Borgo, Elena, additional, Luminari, Stefano, additional, Zucca, Emanuele, additional, and Thieblemont, Catherine, additional

Published
2024
Full Text
View/download PDF

9. A MALT lymphoma prognostic index

Author

Thieblemont, Catherine, Cascione, Luciano, Conconi, Annarita, Kiesewetter, Barbara, Raderer, Markus, Gaidano, Gianluca, Martelli, Maurizio, Laszlo, Daniele, Coiffier, Bertrand, Lopez Guillermo, Armando, Torri, Valter, Cavalli, Franco, Johnson, Peter W., and Zucca, Emanuele

Published
2017
Full Text
View/download PDF

10. Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi

Author

Nizzoli, Maria E., primary, Manni, Martina, additional, Ghiggi, Chiara, additional, Pulsoni, Alessandro, additional, Musuraca, Gerardo, additional, Merli, Michele, additional, Califano, Catello, additional, Bari, Alessia, additional, Massaia, Massimo, additional, Conconi, Annarita, additional, Musto, Pellegrino, additional, Mannina, Donato, additional, Perrone, Tommasina, additional, Re, Francesca, additional, Galimberti, Sara, additional, Gini, Guido, additional, Capponi, Monia, additional, Vitolo, Umberto, additional, Usai, Sara V., additional, Stefani, Piero M., additional, Ballerini, Filippo, additional, Liberati, Anna M., additional, Pennese, Elsa, additional, Pastore, Domenico, additional, Skrypets, Tetiana, additional, Catellani, Hillary, additional, Marcheselli, Luigi, additional, Federico, Massimo, additional, and Luminari, Stefano, additional

Published
2023
Full Text
View/download PDF

12. Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., additional, Habermann, Thomas M., additional, Link, Brian K., additional, Thieblemont, Catherine, additional, Conconi, Annarita, additional, Larson, Melissa C., additional, Cascione, Luciano, additional, Zhao, Wei, additional, Cerhan, James R., additional, Zucca, Emanuele, additional, and Lossos, Izidore S., additional

Published
2022
Full Text
View/download PDF

13. Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma

Author

Alderuccio, Juan Pablo, Reis, Isildinha M, Habermann, Thomas M, Link, Brian K, Thieblemont, Catherine, Conconi, Annarita, Larson, Melissa C, Cascione, Luciano, Zhao, Wei, Cerhan, James R, Zucca, Emanuele, and Lossos, Izidore S

Subjects
610 Medizin und Gesundheit
Abstract

Extranodal marginal zone lymphoma (EMZL) is a heterogeneous disease with a subset of patients exhibiting a more aggressive course. We previously reported that EMZL with multiple mucosal sites (MMS) at diagnosis is characterized by shorter survival. To better recognize patients with different patterns of progression-free survival (PFS) we developed and validated a new prognostic index primarily based on patient's disease characteristics. We derived the "Revised mucosa-associated lymphoid tissue International Prognostic Index" (Revised MALT-IPI) in a large data set (n=397) by identifying candidate variables that showed highest prognostic association with PFS. The revised MALT-IPI was validated in two independent cohorts, from the University of Iowa/Mayo Clinic (n=297) and from IELSG-19 study (n=400). A stepwise Cox regression analysis yielded a model including four independent predictors of shorter PFS. Revised MALT-IPI has scores ranging from 0 to 5, calculated as a sum of 1 point for each of the following- age >60 years, elevated LDH, and stage III-IV; and 2 points for MMS. In the training cohort, the Revised MALT-IPI defined 4 risk groups: low risk (score 0, reference group), low-medium risk (score 1, HR=1.85, P=0.008), medium-high risk (score 2, HR=3.84, P

Published
2022
Full Text
View/download PDF

14. Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)

Author

Benevolo, Giulia, primary, Ferrero, Simone, additional, Villivà, Nicoletta, additional, Castiglione, Anna, additional, Monaco, Federico, additional, Boccomini, Carola, additional, Cabras, Maria Giuseppina, additional, Califano, Catello, additional, Casula, Paolo, additional, Cavallo, Federica, additional, Conconi, Annarita, additional, Drandi, Daniela, additional, Gaidano, Gianluca, additional, Gregorini, Anna Ines, additional, Felici, Stefano, additional, Ferrante, Martina, additional, Mannina, Donato, additional, Molinari, Anna Lia, additional, Musto, Pellegrino, additional, Musuraca, Gerardo, additional, Merli, Michele, additional, Sartori, Roberto, additional, Tani, Monica, additional, Varettoni, Marzia, additional, Vitolo, Umberto, additional, and Orsucci, Lorella, additional

Published
2021
Full Text
View/download PDF

15. Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

Author

Luminari, Stefano, primary, Nizzoli, Maria Elena, additional, Chiarenza, Annalisa, additional, Mannina, Donato, additional, Tucci, Alessandra, additional, Boccomini, Carola, additional, Farina, Lucia, additional, Olivieri, Jacopo, additional, Marcheselli, Luigi, additional, Ferrero, Simone, additional, Arcaini, Luca, additional, Pulsoni, Alessandro, additional, Musuraca, Gerardo, additional, Califano, Catello, additional, Merli, Michele, additional, Bari, Alessia, additional, Conconi, Annarita, additional, Re, Francesca, additional, Balzarotti, Monica, additional, Ladetto, Marco, additional, Patti, Caterina, additional, Pinto, Antonello, additional, Cabras, Maria Giuseppina, additional, Musto, Pellegrino, additional, Gini, Guido, additional, Arcari, Annalisa, additional, Manni, Martina, additional, Versari, Annibale, additional, and Federico, Massimo, additional

Published
2021
Full Text
View/download PDF

17. Rituximab and Lenalidomide (R 2) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Author

Boccomini, Carola, Botto, Barbara, Evangelista, Andrea, Zilioli, Vittorio Ruggero, Anastasia, Antonella, Cavallo, Federica, Merli, Francesco, Zanni, Manuela, Tani, Monica, Chiarenza, Annalisa, Liberati, Anna Marina, Conconi, Annarita, Corradini, Paolo, Bari, Alessia, Annechini, Giorgia, Gaidano, Gianluca, Spina, Michele, Sartori, Roberto, Castellino, Claudia, Puccini, Benedetta, Arcari, Annalisa, Bigliardi, Sara, Matta, Giorgia, Merli, Michele, Mannina, Donato, Marino, Dario, Galieni, Piero, Ciambelli, Fabrizio, Musuraca, Gerardo, Bottelli, Chiara, Muzi, Cristina, Ferrero, Simone, Luminari, Stefano, Ladetto, Marco, Ciccone, Giovannino, and Vitolo, Umberto

Published
2023
Full Text
View/download PDF

18. Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi

Author

Merli, Francesco, Cavallo, Federica, Salvi, Flavia, Tucci, Alessandra, Musuraca, Gerardo, Nassi, Luca, Merli, Michele, Tani, Monica, Gini, Guido, Ferrari, Angela, Molinari, Anna Lia, Liberati, Anna Marina, Conconi, Annarita, Matteucci, Paola, Bari, Alessia, Scalone, Renato, Ferrero, Simone, Zanni, Manuela, Mammi, Caterina, and Luminari, Stefano

Published
2020
Full Text
View/download PDF

19. ABCL-135: RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Author

Rodgers, Thomas, primary, Luigi Zinzani, Pier, additional, Marino, Dario, additional, Frezzato, Maurizio, additional, Maria Barbui, Anna, additional, Castellino, Claudia, additional, Meli, Erika, additional, Conconi, Annarita, additional, Cascavilla, Nicola, additional, Cavallo, Federica, additional, H Fowler, Nathan, additional, Feinberg, Bruce, additional, Tillmanns, Sascha, additional, Parche, Stephan, additional, Fingerle-Rowson, Günter, additional, Winderlich, Mark, additional, Ambarkhane, Sumeet, additional, Salles, Gilles, additional, and Nowakowski, Grzegorz, additional

Published
2020
Full Text
View/download PDF

21. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals

Author

Conconi, Annarita, Zucca, Emanuele, Margiotta-Casaluci, Gloria, Darling, Katharine, Hasse, Barbara, Battegay, Manuel, Staehelin, Cornelia, Novak, Urban, Schmid, Patrick, Scherrer, Alexandra, Dirnhofer, Stephan, Kwee, Ivo, Nassi, Luca, Cavalli, Franco, Gaidano, Gianluca, Bertoni, Francesco, Bernasconi, Enos, Swiss HIV Cohort Study, University of Zurich, and Bertoni, Francesco

Subjects
10234 Clinic for Infectious Diseases, 2720 Hematology, 610 Medicine & health, 2730 Oncology, 1306 Cancer Research
Published
2018

22. Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M, additional, Habermann, Thomas M., additional, Link, Brian K., additional, Thieblemont, Catherine, additional, Conconi, Annarita, additional, Larson, Melissa C, additional, Cascione, Luciano, additional, Zhao, Wei, additional, Cerhan, James R., additional, Zucca, Emanuele, additional, and Lossos, Izidore S., additional

Published
2019
Full Text
View/download PDF

23. Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome

Author

Vannata, Barbara, primary, Conconi, Annarita, additional, Winkler, Jonas, additional, Cascione, Luciano, additional, Margiotta Casaluci, Gloria, additional, Nassi, Luca, additional, Moia, Riccardo, additional, Pirosa, Maria Cristina, additional, Moccia, Alden A., additional, Stathis, Anastasios, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, and Zucca, Emanuele, additional

Published
2019
Full Text
View/download PDF

24. Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice

Author

Broccoli, Alessandro, primary, Casadei, Beatrice, additional, Chiappella, Annalisa, additional, Visco, Carlo, additional, Tani, Monica, additional, Cascavilla, Nicola, additional, Conconi, Annarita, additional, Balzarotti, Monica, additional, Cox, Maria Christina, additional, Marino, Dario, additional, Goldaniga, Maria Cecilia, additional, Marasca, Roberto, additional, Tecchio, Cristina, additional, Patti, Caterina, additional, Musuraca, Gerardo, additional, Devizzi, Liliana, additional, Monaco, Federico, additional, Romano, Alessandra, additional, Fama, Angelo, additional, Zancanella, Michelle, additional, Paolini, Rossella, additional, Rigacci, Luigi, additional, Castellino, Claudia, additional, Gaudio, Francesco, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2019
Full Text
View/download PDF

25. Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenström Macroglobulinemia Patients

Author

Benevolo, Giulia, primary, Ferrero, Simone, additional, Andriani, Alessandro, additional, Castiglione, Anna, additional, Baraldi, Anna, additional, Boccomini, Carola, additional, Cabras, Maria Giuseppina, additional, Califano, Catello, additional, Cavallo, Federica, additional, Conconi, Annarita, additional, Curreli, Luigi, additional, Drandi, Daniela, additional, Gaidano, Gianluca, additional, Felici, Stefano, additional, Ferrante, Martina, additional, Mannina, Donato, additional, Merli, Michele, additional, Molinari, Anna Lia, additional, Musto, Pellegrino, additional, Musuraca, Gerardo, additional, Rossi, Francesca Gaia, additional, Sartori, Roberto, additional, Tani, Monica, additional, Varettoni, Marzia, additional, Vitolo, Umberto, additional, and Orsucci, Lorella, additional

Published
2018
Full Text
View/download PDF

26. High‐dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL‐GITMO

Author

Avivi, Irit, primary, Arcaini, Luca, additional, Ferretti, Virginia V., additional, Boumendil, Ariane, additional, Finel, Hervé, additional, Milone, Giuseppe, additional, Zaja, Francesco, additional, Liliana, Devizzi, additional, Musso, Maurizio, additional, Didier, Blaise, additional, Bachy, Emmanuel, additional, Wattad, Mohammed, additional, Nicolas‐Virelizier, Emmanuelle, additional, Gramatzki, Martin, additional, Bourhis, Jean‐Henri, additional, Caillot, Denis, additional, Haenel, Anette, additional, Held, Gerhard, additional, Thieblemont, Catherine, additional, Jindra, Pavel, additional, Pohlreich, David, additional, Guilhot, François, additional, Kroschinsky, Frank, additional, Wahlin, Björn, additional, Scheid, Christof, additional, Ifrah, Norbert, additional, Berthou, Christian, additional, Dreger, Peter, additional, Montoto, Silvia, additional, and Conconi, Annarita, additional

Published
2018
Full Text
View/download PDF

28. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (MGD) Service d'hématologie, Zucca, Emanuele, Conconi, Annarita, Martinelli, Giovanni, Bouabdallah, Reda, Tucci, Alessandra, Vitolo, Umberto, Martelli, Maurizio, Pettengell, Ruth, Salles, Gilles, Sebban, Catherine, Guillermo, Armando Lopez, Pinotti, Graziella, Devizzi, Liliana, Morschhauser, Franck, Tilly, Hervé, Torri, Valter, Hohaus, Stefan, Ferreri, Andrés J M, Zachée, Pierre, Bosly, André, Haioun, Corinne, Stelitano, Caterina, Bellei, Monica, Ponzoni, Maurilio, Copie-Bergman, Christiane, Jack, Andrew, Campo, Elias, Mazzucchelli, Luca, Cavalli, Franco, Johnson, Peter, Thieblemont, Catherine, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (MGD) Service d'hématologie, Zucca, Emanuele, Conconi, Annarita, Martinelli, Giovanni, Bouabdallah, Reda, Tucci, Alessandra, Vitolo, Umberto, Martelli, Maurizio, Pettengell, Ruth, Salles, Gilles, Sebban, Catherine, Guillermo, Armando Lopez, Pinotti, Graziella, Devizzi, Liliana, Morschhauser, Franck, Tilly, Hervé, Torri, Valter, Hohaus, Stefan, Ferreri, Andrés J M, Zachée, Pierre, Bosly, André, Haioun, Corinne, Stelitano, Caterina, Bellei, Monica, Ponzoni, Maurilio, Copie-Bergman, Christiane, Jack, Andrew, Campo, Elias, Mazzucchelli, Luca, Cavalli, Franco, Johnson, Peter, and Thieblemont, Catherine

Abstract

Purpose There is no consensus on the optimal systemic treatment of patients with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. The IELSG-19 phase III study, to our knowledge, was the first such study to address the question of first-line treatment in a randomized trial. Patients and Methods Eligible patients were initially randomly assigned (1:1 ratio) to receive either chlorambucil monotherapy (6 mg/m(2)/d orally on weeks 1 to 6, 9 to 10, 13 to 14, 17 to 18, and 21 to 22) or a combination of chlorambucil (same schedule as above) and rituximab (375 mg/m(2) intravenously on day 1 of weeks 1, 2, 3, 4, 9, 13, 17, and 21). After the planned enrollment of 252 patients, the protocol was amended to continue with a three-arm design (1:1:6 ratio), with a new arm that included rituximab alone (same schedule as the combination arm) and with a final sample size of 454 patients. The main end point was event-free survival (EFS). Analysis of chlorambucil versus the combination arm was performed and reported separately before any analysis of the third arm. Results At a median follow-up of 7.4 years, addition of rituximab to chlorambucil led to significantly better EFS (hazard ratio, 0.54; 95% CI, 0.38 to 0.77). EFS at 5 years was 51% (95% CI, 42 to 60) with chlorambucil alone, 50% (95% CI, 42 to 59) with rituximab alone, and 68% (95% CI, 60 to 76) with the combination ( P = .0009). Progression-free survival was also significantly better with the combination ( P = .0119). Five-year overall survival was approximately 90% in each arm. All treatments were well tolerated. No unexpected toxicities were recorded. Conclusion Rituximab in combination with chlorambucil demonstrated superior efficacy in mucosa-associated lymphoid tissue lymphoma; however, improvements in EFS and progression-free survival did not translate into longer overall survival.

Published
2017

29. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions

Author

Gobba, Stefania, primary, Moccia, Alden A., additional, Gulden-Sala, Wiebke, additional, Conconi, Annarita, additional, Diem, Stefan, additional, Cascione, Luciano, additional, Iacoboni, Gloria, additional, Margiotta-Casaluci, Gloria, additional, Aprile von Hohenstaufen, Kathrin, additional, Stathis, Anastasios, additional, Hitz, Felicitas, additional, Pinotti, Graziella, additional, Gaidano, Gianluca, additional, and Zucca, Emanuele, additional

Published
2017
Full Text
View/download PDF

30. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy

Author

Zucca, Emanuele, primary, Conconi, Annarita, additional, Martinelli, Giovanni, additional, Bouabdallah, Reda, additional, Tucci, Alessandra, additional, Vitolo, Umberto, additional, Martelli, Maurizio, additional, Pettengell, Ruth, additional, Salles, Gilles, additional, Sebban, Catherine, additional, Guillermo, Armando Lopez, additional, Pinotti, Graziella, additional, Devizzi, Liliana, additional, Morschhauser, Franck, additional, Tilly, Hervé, additional, Torri, Valter, additional, Hohaus, Stefan, additional, Ferreri, Andrés J.M., additional, Zachée, Pierre, additional, Bosly, André, additional, Haioun, Corinne, additional, Stelitano, Caterina, additional, Bellei, Monica, additional, Ponzoni, Maurilio, additional, Moreau, Anne, additional, Jack, Andrew, additional, Campo, Elias, additional, Mazzucchelli, Luca, additional, Cavalli, Franco, additional, Johnson, Peter, additional, and Thieblemont, Catherine, additional

Published
2017
Full Text
View/download PDF

31. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study

Author

Ceriani, Luca, primary, Martelli, Maurizio, additional, Conconi, Annarita, additional, Zinzani, Pier L., additional, Ferreri, Andrés J. M., additional, Botto, Barbara, additional, Stelitano, Caterina, additional, Gotti, Manuel, additional, Cabras, Maria G., additional, Rigacci, Luigi, additional, Giovanella, Luca, additional, Zucca, Emanuele, additional, and Johnson, Peter W. M., additional

Published
2017
Full Text
View/download PDF

32. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)

Author

Jackson, Amie E, Mian, Michael, Kalpadakis, Christina, Pangalis, Gerassimos A, Stathis, Anastasios, Porro, Elena, Conconi, Annarita, Cortelazzo, Sergio, Gaidano, Gianluca, Lopez, Armando, Guillermo, Null, Johnson, Peter W, Martelli, Maurizio, Martinelli, Giovanni, Thieblemont, Catherine, Mcphail, Ellen D, Copie Bergman, Christiane, Pileri, Stefano A, Jack, Andrew, Campo, Elias, Mazzucchelli, Luca, Ristow, Kay, Habermann, Thomas M, Cavalli, Franco, Nowakowski, Grzegorz S, and Zucca, Emanuele

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, Lymphoid tissue, Lymphoma, Hematologic Malignancies, B-cell, Disease, Salivary glands, Gastroenterology, Disease-Free Survival, Young Adult, International Prognostic Index, Internal medicine, Medicine, Humans, Aged, Aged, 80 and over, Salivary gland, business.industry, Marginal zone, Sjögren's disease, MALT lymphoma, Lymphoma, B-Cell, Marginal Zone, Middle Aged, medicine.disease, Prognosis, Salivary Gland Neoplasms, Surgery, Lymphatic system, medicine.anatomical_structure, Sjogren's Syndrome, Treatment Outcome, Oncology, Chemotherapy, Adjuvant, Rituximab, Female, business, Mucosa-associated lymphoid tissue, medicine.drug
Abstract

Background. The salivary gland is one of the most common sites involved by nongastric, extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). A large series of patients with long-term follow-up has not been documented. This multicenter, international study sought to characterize the clinical characteristics, treatment, and natural history of salivary gland MALT lymphoma. Methods. Patients with biopsy-confirmed salivary gland MALT lymphoma were identified from multiple international sites. Risk factors, treatment, and long-term outcomes were evaluated. Results. A total of 247 patients were evaluated; 76% presented with limited-stage disease. There was a history of autoimmune disorder in 41%, with Sjögren disease being the most common (83%). Fifty-seven percent of patients were initially treated with local therapy with surgery, radiation, or both; 37 of patients were treated with systemic therapy initially, with 47% of those receiving rituximab; and 6% of patients were observed. The median overall survival (OS) was 18.3 years. The median progression-free survival (PFS) following primary therapy was 9.3 years. There was no difference in the outcomes between patients receiving local or systemic therapy in first-line management. On multivariate analysis, age Conclusion. Salivary gland MALT lymphoma has an excellent prognosis regardless of initial treatment, and patients with Sjögren disease have improved survival. Risks for long-term complications must be weighed when determining initial therapy. Implications for Practice: Patients with salivary gland extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) have an excellent prognosis, particularly those with associated Sjögren's disease. A wide range of available therapies may provide similar durable rates of disease control and survival. Therefore, an important goal in selection of therapy should be to minimize morbidity from treatment. When determining initial therapy for these patients, practitioners should consider the potential side effects and long-term toxicities of treatment.

Published
2015

33. LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL)

Author

Boccomini, Carola, primary, Ladetto, Marco, additional, Dutto, Francesca, additional, Ferrero, Simone, additional, Baldini, Luca, additional, Bottelli, Chiara, additional, Castellino, Claudia, additional, Chiarenza, Annalisa, additional, Conconi, Annarita, additional, De Angelis, Federico, additional, Evangelista, Andrea, additional, Hohaus, Stefan, additional, Merli, Francesco, additional, Puccini, Benedetta, additional, Rusconi, Chiara, additional, Russo, Eleonora, additional, Sacchi, Stefano, additional, Volpetti, Stefano, additional, Rossi, Giuseppe, additional, and Vitolo, Umberto, additional

Published
2015
Full Text
View/download PDF

34. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.

Author

Gobba, Stefania, Moccia, Alden A., Gulden‐Sala, Wiebke, Conconi, Annarita, Diem, Stefan, Cascione, Luciano, Iacoboni, Gloria, Margiotta‐Casaluci, Gloria, Aprile von Hohenstaufen, Kathrin, Stathis, Anastasios, Hitz, Felicitas, Pinotti, Graziella, Gaidano, Gianluca, Zucca, Emanuele, Gulden-Sala, Wiebke, and Margiotta-Casaluci, Gloria

Subjects
ANTINEOPLASTIC agents, B cell lymphoma, COMPARATIVE studies, IMMUNOTHERAPY, RESEARCH methodology, MEDICAL cooperation, PROGNOSIS, RESEARCH, EVALUATION research, TREATMENT effectiveness, RETROSPECTIVE studies, IMPACT of Event Scale
Abstract

Little information is available on the very elderly patients with diffuse large B-cell lymphoma (DLBCL). We performed a retrospective analysis of 281 patients >80 years old with newly diagnosed DLBCL treated in 4 referral institutions in Switzerland and Northern Italy. Primary end points were overall survival, progression-free survival, and cause-specific survival. Systemic chemotherapy was given to 239 patients, and 119 of them received rituximab in their initial treatment. At a median follow-up of 5.5 years, 5-year progression-free survival was 26% (95% confidence interval [CI], 20-32%), 5-year overall survival was 31% (95% CI, 25-37%), and 5-year cause-specific survival was 48% (95% CI, 41-55%) for the entire cohort. Rituximab and/or anthracyclines as part of initial treatment were associated with improved outcome. Cause-specific survival in patients receiving both agents approximated 60% at 5 years. At multivariate analysis, rituximab use maintained a significant prognostic impact after controlling for age, performance status, stage, haemoglobin, and lactate dehydrogenase levels. The International Prognostic Index as well as the more recently proposed revised-International Prognostic Index and National Comprehensive Cancer Center Network-International Prognostic Index could discriminate patients with significantly different outcomes. Albeit very elderly and potentially frail, there may be a potential for cure in fit DLBCL patients ≥80 years old. Accurate selection of patients able to tolerate proper immunochemotherapy is crucial. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

35. IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

Author

Stathis, Anastasios, Gregorini, Anna, Gressin, Remy, Orsucci, Lorella, Perrot, Aurore, Tani, Monica, Coiffier, Bertrand, Musuraca, Gerardo, Guieze, Romain, Marino, Dario, Gini, Guido, Ferrari, Angela, Gyan, Emmanuel, Morschhauser, Franck, Palombi, Francesca, Cavallo, Federica, Le Gouill, Steven, Tilly, Herve, Salvi, Flavia, Conconi, Annarita, Cabras, Maria Giuseppina, Capochiani, Enrico, Califano, Catello, Molinari, Anna Lia, Pulsoni, Alessandro, Ielmini, Nicoletta, Luminari, Stefano, Cavalli, Franco, Zucca, Emanuele, and Thieblemont, Catherine

Published
2017
Full Text
View/download PDF

36. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)

Author

Jackson, Amie E., primary, Mian, Michael, additional, Kalpadakis, Christina, additional, Pangalis, Gerassimos A., additional, Stathis, Anastasios, additional, Porro, Elena, additional, Conconi, Annarita, additional, Cortelazzo, Sergio, additional, Gaidano, Gianluca, additional, Guillermo, Armando Lopez, additional, Johnson, Peter W., additional, Martelli, Maurizio, additional, Martinelli, Giovanni, additional, Thieblemont, Catherine, additional, McPhail, Ellen D., additional, Copie-Bergman, Christiane, additional, Pileri, Stefano A., additional, Jack, Andrew, additional, Campo, Elias, additional, Mazzucchelli, Luca, additional, Ristow, Kay, additional, Habermann, Thomas M., additional, Cavalli, Franco, additional, Nowakowski, Grzegorz S., additional, and Zucca, Emanuele, additional

Published
2015
Full Text
View/download PDF

37. High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study

Author

Avivi, Irit, primary, Arcaini, Luca, additional, Ferretti, Virginia, additional, Boumendil, Ariane, additional, Finel, Herve, additional, Pascutto, Cristiana, additional, Milone, Giuseppe, additional, Zaja, Francesco, additional, Liliana, Devizzi, additional, Musso, Maurizio, additional, Didier, Blaise, additional, Salles, Gilles, additional, Wattad, Mohammed, additional, Nicolas-Virelizier, Emmanuelle, additional, Gramatzki, Martin, additional, Bourhis, Jean-Henri, additional, Caillot, Denis, additional, Haenel, Shannon, additional, Haenel, Anette, additional, Held, Gerhard, additional, Thieblemont, Catherine, additional, Jindra, Pavel, additional, Pohlreich, David, additional, Guilhot, François, additional, Bornhaeuser, Martin, additional, Ljungman, Per T., additional, Scheid, Christof, additional, Ifrah, Norbert, additional, Berthou, Christian, additional, Dreger, Peter, additional, Montoto, Silvia, additional, and Conconi, Annarita, additional

Published
2014
Full Text
View/download PDF

38. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18- FDG PET/ CT quantitative parameters in the International Extranodal Lymphoma Study Group ( IELSG) 26 study.

Author

Ceriani, Luca, Martelli, Maurizio, Conconi, Annarita, Zinzani, Pier L., Ferreri, Andrés J. M., Botto, Barbara, Stelitano, Caterina, Gotti, Manuel, Cabras, Maria G., Rigacci, Luigi, Giovanella, Luca, Zucca, Emanuele, and Johnson, Peter W. M.

Subjects
MEDIASTINAL tumors, B cells, POSITRON emission tomography, GLYCOLYSIS, PROGNOSIS
Abstract

The International Extranodal Lymphoma Study Group-26 study evaluated the prognostic role of 18-fluorodeoxyglucose positron-emission tomography ( PET) in primary mediastinal large B-cell lymphoma. We assessed quantitative PET parameters at diagnosis and post-treatment in 100 patients. The end-of-therapy total lesion glycolysis ( TLG) was the best individual outcome predictor, but the combination of baseline TLG and end-of-therapy visual analysis with Deauville Score ( DS) showed a better positive predictive value. A model in which baseline TLG is combined with interim DS might identify patients with shorter progression-free survival. PET metrics combined with interim DS may allow early risk assessment and warrants further studies. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

39. Early complete response a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy

Author

Bommier, Côme, Zucca, Emanuele, Chevret, Sylvie, Conconi, Annarita, Nowakowski, Grzegorz, Maurer, Matthew J., Cerhan, James R., Thieblemont, Catherine, and Lambert, Jérôme

Abstract

•Surrogate markers provide early decision-making end points for regulatory agencies; they serve as substitutes for long-term end points.•In extranodal MZL, CR24 mediates 90% and TTCR24 captures 95% of treatment effect on 8-year PFS, which makes them valid early indicators.

Published
2023
Full Text
View/download PDF

40. Bortezomib-Dexamethasone Re-Treatment at Biochemical Relapse Vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II Multi-Center, Randomized Study

Author

Mina, Roberto, Larocca, Alessandra, Belotti, Angelo, Di Raimondo, Francesco, Baraldi, Anna, Offidani, Massimo, Marchetti, Monia, Ria, Roberto, Conconi, Annarita, Pescosta, Norbert, Grasso, Mariella, Cetani, Giusy, Cafro, Anna Maria, Passera, Roberto, Troia, Rossella, Semenzato, Gianpietro, Giuliani, Nicola, Ballanti, Stelvio, Cellini, Claudia, Liberati, Anna Marina, Caravita di Toritto, Tommaso, Petrucci, Maria Teresa, Musto, Pellegrino, Palumbo, Antonio, Sonneveld, Pieter, and Boccadoro, Mario

Abstract

Background:The pattern of multiple myeloma (MM) relapses includes both biochemical relapses, characterized by the increase of monoclonal paraprotein in absence of organ dysfunction and CRAB symptoms, and clinical relapses, when the increase of monoclonal protein is associated with organ dysfunction. The International Myeloma Working Group (IMWG) recommends starting the subsequent treatment when either clinical relapse or a significant paraprotein increase occur (Rajkumar S. V. et al., Blood2011 Feb 3; 1sted.). To date, no data are available about the benefit of treatment at biochemical relapse rather than waiting for clinical relapse. Data from the RETRIEVE study suggested that re-treatment with bortezomib is safe and effective (Petrucci M. T. et al., Haematologica2010; 95 (s2):152). Here we report the results of a phase II multi-center, randomized study that investigated the efficacy and safety of bortezomib re-treatment at biochemical relapse compared to observation until clinical relapse.

Published
2017
Full Text
View/download PDF

41. Lenalidomide in Pretreated Patients with Diffuse Large B‐Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice

Author

Nicola Cascavilla, Cristina Tecchio, Carlo Visco, Annalisa Chiappella, Maria Christina Cox, Roberto Marasca, Rossella Paolini, Beatrice Casadei, Gerardo Musuraca, Caterina Patti, Michelle Zancanella, Annarita Conconi, Maria Goldaniga, Angelo Fama, Dario Marino, Francesco Gaudio, Claudia Castellino, Alessandra Romano, Luigi Rigacci, Monica Tani, Monica Balzarotti, Federico Monaco, Alessandro Broccoli, Lisa Argnani, Liliana Devizzi, Pier Luigi Zinzani, Broccoli, Alessandro, Casadei, Beatrice, Chiappella, Annalisa, Visco, Carlo, Tani, Monica, Cascavilla, Nicola, Conconi, Annarita, Balzarotti, Monica, Cox, Maria Christina, Marino, Dario, Goldaniga, Maria Cecilia, Marasca, Roberto, Tecchio, Cristina, Patti, Caterina, Musuraca, Gerardo, Devizzi, Liliana, Monaco, Federico, Romano, Alessandra, Fama, Angelo, Zancanella, Michelle, Paolini, Rossella, Rigacci, Luigi, Castellino, Claudia, Gaudio, Francesco, Argnani, Lisa, and Zinzani, Pier Luigi

Subjects
0301 basic medicine, Male, Cancer Research, Diffuse large B‐cell lymphoma, Lymphoma, Hematologic Malignancies, Efficacy, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, 80 and over, Lenalidomide, Aged, 80 and over, Remission Induction, Diffuse large B-cell lymphoma, Middle Aged, Prognosis, Diffuse, Treatment Outcome, Oncology, Local, Italy, 030220 oncology & carcinogenesis, Female, Lymphoma, Large B-Cell, Diffuse, Rituximab, medicine.drug, Adult, medicine.medical_specialty, Real life, Refractory, Relapsed, Context (language use), Neutropenia, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Large B-Cell, Humans, Progression-free survival, Aged, business.industry, Retrospective cohort study, medicine.disease, 030104 developmental biology, Neoplasm Recurrence, Neoplasm Recurrence, Local, business, Febrile neutropenia
Abstract

Background Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma subtype, and approximately 50% of the patients are >60 years of age. Patients with relapsed/refractory (rr) disease have a poor prognosis with currently available treatments. Lenalidomide is available in Italy for patients with rrDLBCL based on a local disposition of the Italian Drug Agency. Subjects, Materials, and Methods An observational retrospective study was conducted in 24 Italian hematology centers with the aim to improve information on effectiveness and safety of lenalidomide use for rrDLBCL in real practice. Results One hundred fifty-three patients received lenalidomide for 21/28 days with a median of four cycles. At the end of therapy, there were 36 complete responses (23.5%) and 9 partial responses with an overall response rate (ORR) of 29.4%. In the elderly (>65 years) subset, the ORR was 33.6%. With a median follow-up of 36 months, median overall survival was reached at 12 months and median disease-free survival was not reached at 62 months. At the latest available follow-up, 29 patients are still in response out of therapy. Median progression-free survivals differ significantly according to age (2.5 months vs. 9.5 in the younger vs. elderly group, respectively) and to disease status at the latest previous therapy (15 months for relapsed patients vs. 3.5 for refractory subjects). Toxicities were manageable, even if 30 of them led to an early drug discontinuation. Conclusion Lenalidomide therapy for patients with rrDLBCL is effective and tolerable even in a real-life context, especially for elderly patients. Implications for Practice Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, and approximately 50% of the patients are >60 years of age. Patients with relapsed/refractory (rr) disease have a poor prognosis, reflected by the remarkably short life expectancy of 12 months with currently available treatments. The rrDLBCL therapeutic algorithm is not so well established because data in the everyday clinical practice are still poor. Lenalidomide for patients with rrDLBCL is effective and tolerable even in a real-life context, especially for elderly patients.

Published
2019

42. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma

Author

Luca Ceriani, Anastasios Stathis, Luciano Cascione, Alice Di Rocco, Maurizio Martelli, Pier Luigi Zinzani, Elena Porro, Monica Bellei, Luca Giovanella, Andrés J.M. Ferreri, Peter Johnson, Annarita Conconi, Emanuele Zucca, Lisa Milan, Kelly Cozens, Franco Cavalli, Ceriani, Luca, Milan, Lisa, Martelli, Maurizio, Ferreri, Andrés J M, Cascione, Luciano, Zinzani, Pier Luigi, Di Rocco, Alice, Conconi, Annarita, Stathis, Anastasio, Cavalli, Franco, Bellei, Monica, Cozens, Kelly, Porro, Elena, Giovanella, Luca, Johnson, Peter W, and Zucca, Emanuele

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Immunology, 18FDG-PET/CT, Kaplan-Meier Estimate, Mediastinal Neoplasms, Biochemistry, 030218 nuclear medicine & medical imaging, MH, PMBCL, 03 medical and health sciences, 0302 clinical medicine, International Prognostic Index, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Statistical significance, Internal medicine, medicine, Humans, B-cell lymphoma, Aged, Proportional Hazards Models, medicine.diagnostic_test, Proportional hazards model, business.industry, Mediastinum, B-cell lymphoma, 18FDG-PET/CT, primary mediastinal B-cell lymphoma, Cell Biology, Hematology, Middle Aged, Prognosis, medicine.disease, Combined Modality Therapy, Lymphoma, medicine.anatomical_structure, ROC Curve, Positron emission tomography, 030220 oncology & carcinogenesis, Female, Primary mediastinal B-cell lymphoma, business, Biomarkers
Abstract

An important unmet need in the management of primary mediastinal B-cell lymphoma (PMBCL) is to identify the patients for whom first-line therapy will fail to intervene before the lymphoma becomes refractory. High heterogeneity of intratumoral 18F-fluorodeoxyglucose (18FDG) uptake distribution on positron emission tomography/computed tomography (PET/CT) scans has been suggested as a possible marker of chemoresistance in solid tumors. In the present study, we investigated the prognostic value of metabolic heterogeneity (MH) in 103 patients with PMBCL prospectively enrolled in the International Extranodal Lymphoma Study Group (IELSG) 26 study, aimed at clarifying the role of PET in this lymphoma subtype. MH was estimated using the area under curve of cumulative standardized uptake value-volume histogram (AUC-CSH) method. Progression-free survival at 5 years was 94% vs 73% in low- and high-MH groups, respectively (P = .0001). In a Cox model of progression-free survival including dichotomized MH, metabolic tumor volume, total lesion glycolysis (TLG), international prognostic index, and tumor bulk (mediastinal mass > 10 cm), as well as age as a continuous variable, only TLG (P < .001) and MH (P < .001) retained statistical significance. Using these 2 features to construct a simple prognostic model resulted in early and accurate (positive predictive value, 89%; negative predictive value, ≥90%) identification of patients at high risk for progression at a point that would allow the use of risk-adapted treatments. This may provide an important opportunity for the design of future trials aimed at helping the minority of patients who harbor chemorefractory PMBCL. The study is registered at ClinicalTrials.gov as NCT00944567.

Published
2018

43. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: A retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO

Author

Virginia Valeria Ferretti, Christof Scheid, Frank Kroschinsky, Ariane Boumendil, Gerhard Held, Denis Caillot, Björn E. Wahlin, Norbert Ifrah, Jean Bourhis, Mohammed Wattad, Maurizio Musso, David Pohlreich, Catherine Thieblemont, Peter Dreger, Pavel Jindra, Emmanuelle Nicolas-Virelizier, Anette Haenel, Irit Avivi, Martin Gramatzki, Blaise Didier, Silvia Montoto, Giuseppe Milone, Devizzi Liliana, Christian Berthou, Luca Arcaini, François Guilhot, Emmanuel Bachy, Francesco Zaja, Annarita Conconi, Herve Finel, Avivi, Irit, Arcaini, Luca, Ferretti, Virginia V., Boumendil, Ariane, Finel, Hervé, Milone, Giuseppe, Zaja, Francesco, Liliana, Devizzi, Musso, Maurizio, Didier, Blaise, Bachy, Emmanuel, Wattad, Mohammed, Nicolas-Virelizier, Emmanuelle, Gramatzki, Martin, Bourhis, Jean-Henri, Caillot, Deni, Haenel, Anette, Held, Gerhard, Thieblemont, Catherine, Jindra, Pavel, Pohlreich, David, Guilhot, Françoi, Kroschinsky, Frank, Wahlin, Björn, Scheid, Christof, Ifrah, Norbert, Berthou, Christian, Dreger, Peter, Montoto, Silvia, Conconi, Annarita, Tel Aviv Sourasky Medical Center [Te Aviv], Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Service de Réanimation Médicale [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Lymphoma Working Party, Paris (EBMT), Oncohematology Unit, Oncology Department La Maddalena, Centre Léon Bérard [Lyon], 2nd Medical Department, University Hospital Schleswig-Holstein Campus Kiel, Division of Stem Cell Transplantation and, Institut Gustave Roussy (IGR), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Instituto de Pesquisas Meteorológicas (IPMet), Universidade Estadual Paulista Júlio de Mesquita Filho = São Paulo State University (UNESP), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Department of Hematology and Oncology [Pilsen, Czech Republic], Charles University Hospital Pilsen, Charles University Hospital, CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department I of Internal Medicine, University of Cologne, Hematology Department, Université d'Angers (UA), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHRU Brest - Service d'Hématologie (CHU-Brest-Hemato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Department of Medicine V, Universität Heidelberg [Heidelberg], AOU Maggiore della Carità, Division of Hematology, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Universidade Estadual Paulista Júlio de Mesquita Filho [São José do Rio Preto] (UNESP), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Autologous transplant, [SDV]Life Sciences [q-bio], Transplantation, Autologous, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, Chemoimmunotherapy, Marginal zone lymphoma, Mucosa-associated lymphoid tissue lymphoma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Cumulative incidence, Treatment Failure, Retrospective Studies, business.industry, Hematopoietic Stem Cell Transplantation, MALT lymphoma, Lymphoma, B-Cell, Marginal Zone, Hematology, Middle Aged, Prognosis, medicine.disease, Survival Analysis, 3. Good health, Lymphoma, Transplantation, Regimen, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Rituximab, business, Follow-Up Studies, 030215 immunology, medicine.drug
Abstract

IF 5.128; International audience; The role of autologous stem cell transplantation (ASCT) in patients with marginal zone lymphoma (MZL) is debatable. This study investigated the outcome and prognostic factors affecting the outcome of patients undergoing ASCT for MZL. Eligible patients had non‐transformed nodal, extra‐nodal (MALT) or splenic MZL (SMZL), aged ≥18 years, who underwent a first ASCT between1994 and 2013 and were reported to the European Society for Blood and Marrow Transplantation, Fondazione Italiana Linfomi or Gruppo Italiano Trapianto Di Midollo Osseo registries. The study included 199 patients, [111 MALT lymphoma, 55 nodal MZL (NMZL) and 33 SMZL]. Median age at transplantation was 56 years. The median number of prior therapies was 2 (range 1–8), including rituximab in 71%. 95% had chemosensitive disease. 89% received a chemotherapy‐based high‐dose regimen. There were no significant differences in patient and transplant characteristics between the 3 histological subtypes except for a lower percentage of patients previously treated with rituximab in the MALT sub‐group and more transplants performed in recent years in the other sub‐groups. After a median follow‐up of 5 years, 5‐year cumulative incidence of relapse/progression and non‐relapse mortality were 38% and 9%, respectively. Five‐year event‐free survival (EFS) and overall survival (OS) were 53% and 73%, respectively. Five‐year cumulative incidence of second malignancies was 6%. Multivariate analysis revealed age ≥65 years was associated with a shorter EFS and OS. In addition, patients with SMZL had a shorter OS than those with MALT. ASCT may provide clinical benefit in MZL patients who have failed multiple lines of chemoimmunotherapy.

Published
2018

44. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study

Author

Luigi Rigacci, Maurizio Martelli, Luca Ceriani, Manuel Gotti, Luca Giovanella, Caterina Stelitano, Pier Luigi Zinzani, Emanuele Zucca, Andrés J.M. Ferreri, Annarita Conconi, Barbara Botto, Maria Giuseppina Cabras, Peter Johnson, Ceriani, Luca, Martelli, Maurizio, Conconi, Annarita, Zinzani, Pier L, Ferreri, Andrés J M, Botto, Barbara, Stelitano, Caterina, Gotti, Manuel, Cabras, Maria G, Rigacci, Luigi, Giovanella, Luca, Zucca, Emanuele, and Johnson, Peter W M

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Kaplan-Meier Estimate, Total lesion glycolysis, Prognostic factors, Mediastinal Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Fluorodeoxyglucose F18, Predictive Value of Tests, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, B-cell lymphoma, prognostic factor, Primary mediastinal B-cell lymphoma, Prognostic models, Positron-emission tomography, Positron-emission tomography metrics, Hematology, medicine.diagnostic_test, business.industry, medicine.disease, Prognosis, Lymphoma, 030104 developmental biology, Positron emission tomography, positron-emission tomography metric, 030220 oncology & carcinogenesis, Extranodal lymphoma, Fdg pet ct, Female, Radiology, Lymphoma, Large B-Cell, Diffuse, Radiopharmaceuticals, business, Glycolysis
Abstract

The International Extranodal Lymphoma Study Group-26 study evaluated the prognostic role of 18-fluorodeoxyglucose positron-emission tomography (PET) in primary mediastinal large B-cell lymphoma. We assessed quantitative PET parameters at diagnosis and post-treatment in 100 patients. The end-of-therapy total lesion glycolysis (TLG) was the best individual outcome predictor, but the combination of baseline TLG and end-of-therapy visual analysis with Deauville Score (DS) showed a better positive predictive value. A model in which baseline TLG is combined with interim DS might identify patients with shorter progression-free survival. PET metrics combined with interim DS may allow early risk assessment and warrants further studies.

Published
2017

45. Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment.

Author

Conconi A, Thieblemont C, Cascione L, Torri V, Kiesewetter B, Margiotta Casaluci G, Gaidano G, Raderer M, Cavalli F, Lopez Guillermo A, Johnson PW, and Zucca E

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Disease-Free Survival, Humans, Prognosis, Reproducibility of Results, Rituximab therapeutic use, Lymphoma, B-Cell, Marginal Zone diagnosis, Lymphoma, B-Cell, Marginal Zone drug therapy, Lymphoma, Follicular drug therapy
Abstract

Early progression of disease (POD) within two years from diagnosis is linked with poor overall survival (OS) in follicular lymphoma but its prognostic role is less clear in extranodal marginal zone B-cell lymphoma (EMZL). We sought to identify prognostic factors associated with early POD and to determine whether is associated with inferior OS. We analyzed the impact of early POD in the IELSG19 clinical trial dataset (training set of 401 patients randomly assigned to chlorambucil or rituximab or chlorambucil plus rituximab). Reproducibility was examined in a validation set of 287 patients who received systemic treatment. In both sets, we excluded from the analysis the patients who, within 24 months from treatment start, died without progression or were lost to follow-up without prior progression. OS was calculated from progression in patients with early POD and from 24 months after start of treatment in those without (reference group). Early POD was observed in 69 of the 384 (18%) evaluable patients of the IELSG19 study. Patients with high-risk MALT-IPI were more likely to have early POD (p=0.006). The 10-year OS rate was 64% in the early POD group and 85% in the reference group (HR= 2.42, 95%CI, 1.35-4.34; log-rank P=0.002). This prognostic impact was confirmed in the validation set, in which early POD was observed in 64 out of 224 (29%) evaluable patients with 10-year OS rate of 48% in the early POD group and 71% in the reference group (HR= 2.15, 95%CI, 1.19-3.90; log-rank P=0.009). In patients with EMZL who received front-line systemic treatment, early POD is associated with poorer survival and may represent a useful endpoint in future prospective clinical trials.

Published
2020
Full Text
View/download PDF

46. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.

Author

Conconi A, Zucca E, Margiotta-Casaluci G, Darling K, Hasse B, Battegay M, Staehelin C, Novak U, Schmid P, Scherrer A, Dirnhofer S, Kwee I, Nassi L, Cavalli F, Gaidano G, Bertoni F, and Bernasconi E

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived administration & dosage, Cyclophosphamide administration & dosage, Disease-Free Survival, Doxorubicin administration & dosage, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prednisone administration & dosage, Rituximab, Survival Rate, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, HIV Infections drug therapy, HIV Infections immunology, HIV Infections mortality, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse immunology, Lymphoma, Large B-Cell, Diffuse mortality
Abstract

The prognostic factors and outcome of 58 acquired immunodeficiency syndrome-related diffuse large B-cell lymphoma (AR-DLBCL) patients from the Swiss HIV Cohort Study, diagnosed from 2004 to 2011, were compared with those of 326 immunocompetent (IC)-DLBCL from the Hematology Division of the Amedeo Avogadro University (Italy) and the Oncology Institute of Southern Switzerland. Median follow-up was 6 years; 5-year overall survival (OS) was 68% (95% CI: 63%-73%) in IC-DLBCL and 63% (95% CI: 49%-75%) in AR-DLBCL (P = .220). The acquired immunodeficiency syndrome-related lymphoma international prognostic index predicted OS in AR-DLBCL. Among 148 patients younger than 61 years (40 AR-DLBCL and 108 IC-DLBCL) treated with RCHOP/RCHOP-like regimens, 20 IC-DLBCL and 9 AR-DLBCL patients died and OS was not significantly different. A higher proportion of early deaths occurred in the AR-DLBCL: indeed, 1-year OS was 94% (95% CI: 87%-97%) in IC-DLBCL and 82% (95% CI: 66%-91%) in AR-DLBCL patients. After rituximab and active antiretroviral therapy introduction, AR-DLBCL and IC-DLBCL patients treated with curative intent have similar long-term survival., (© 2018 John Wiley & Sons, Ltd.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results